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The effect of several antiviral drugs on the reactiva-
tion of herpes simplex virus type 1 in explant cultures 
of latently infected mouse trigeminal ganglia was inves-
tigated. Phosphonoacetate and phosphonoformate, 
which act directly on the virus-induced DNA polymer-
ase, require a drug concentration of 400 !Lg/ml for the 
inhibition of virus reactivation in latently infected gan-
glia. Arabinosyladenine and arabinosyladenine mono-
phosphate, which are phosphorylated to triphosphates 
by cellular enzymes and inhibit virus synthesis either 
by blocking the DNA polymerase or by incorporation 
into viral DNA, require a concentration of only 100 !Lg/ 
ml for the inhibition of the reactivation process. Drugs 
that are phosphorylated by the virus-induced thymidine 
kinase, such as acyclovir, arabinosylthymine, bromovi-
nyldeoxyuridine, and three fluorinated pyrimidine nu-
cleosides require the lowest drug concentrations for 
complete inhibition of virus reactivation in latently in-
fected ganglia explant cultures. Our data suggest that 
the inhibition of virus reactivation is dependent not only 
on drug concentration, but also on the number of latently 
infected neurons in the ganglia. 
The abili ty of antiviral compounds to prevent the reactiva-
t ion of latent herpes simplex virus (HSV) infect ions can be 
evaluated in vitro by monitoring t heir effect on explant cultures 
of latently infected sensory ganglia. Using this approach it was 
shown that phosphonoacetate (PAA), arabinosyladenine (Ara-
A) , acyclov ir (ACV), and bromovinyldeoxyuridine (BVDU) can 
prevent virus reactivation in sensory ganglia as long as they 
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Ara-AMP: a rabinosyladenine monophosphate 
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binofuranosyl 
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HSV: herpes simplex virus 
MEM: minimum essent ial medium 
PAA: phosphonoacetate 
PF A: phosphonoformate 
PFU: plaque-forming units 
are present in the explant culture medium [1- 3]. The inhibi tion 
of this process is not followed by the elimination of the latent 
HSV, since after the removal of the drugs from t he explant 
cu lture medium the reactivation of the virus resumes promptly. 
In t his study we have examined the quantitative effect of a 
series of compounds active in preventing HSV replication for 
their ability to prevent virus reactivation in explant cultures of 
latent ly infected trigeminal ganglia of mice which survived a 
primary infection. It appears t hat the quantitative require-
ments for the inhibition of virus reactivation is related to t he 
mechanism of action of the particular ant iviral drugs, and t he 
titer of reactivatable virus in the ganglia. 
MATERIALS AND METHODS 
Trigeminal Ganglia With Established Latent HSV lnfections 
Hairless mice were infected percutaneously in the orofacial area by 
rubbin g in to scarified skin an HSV type 1 virus suspension having a 
t iter of 106 plaque- forming units (PFU) per mi. Afte r 4- 8 weeks the 
surviving mice were killed under pentoba rbital anesthesia by exsangui-
nation through heart puncture. The trigem inal ganglia were removed 
and placed in explant culture. 
Explant Cu.ltures of Trigeminal Ganglia 
Indi vidual ga nglia from 3- 5 mice were mai nta ined sepa ra tely in 24 -
wel l multiplates in Eagle's minimum essent ial medium (MEM) supple-
mented with 2% calf serum , in t he absence or t he presence of inc rea ing 
drug concent rations. After 4 days in cul ture the ganglia were washed 5 
limes, homogenized by sonication, a nd assayed for the presence of 
infectious vi rus in monolayers of huma n foreskin cells (FS7 cell line) 
~rown in 24-well mul t i plates. The virus tite r of positive ganglia homog-
enates was then determined by a pl aque assay in Vero cells. 
Antiviral Drugs 
The compounds used in the experiments were the following: (1 ) 
phosphonoformate (PFA) from Astra La kemedel, Sjodeberg, Sweden; 
(2) arabinosyladenine monophosphate (Ara-AMP) from Parke, Davis 
& Co., Ann Arbor, Michigan; (3) ACV from Wellcome Research Lab-
oratories, Resea rch Triangle Park, Nort h Carolina; (4) a rabinosylt.hy-
mme (Ara-T) from Yamasa Shoyo Co. , Ltd. , Choshi , Japan; (5) BVD 
from Dr. E. DeClercq, Rega Institute, Leuven, Belgium; and (6) three 
1(2-deoxy-2- tluoro-beta-D-a rabinofuranosyl) derivatives: -iodocytosine 
(FIAC), -iodouracil (FIAU) , and methyluracil (FMAU) all from Bristol-
Myers Co., Syracuse, New York. 
Except PFA and Ara -AMP, wh ich are water-soluble, a ll the other 
compounds were dissolved as a stock solu tion in dimethyl sulfoxide, 
from which suitable Lest dilutions were t hen prepared in MEM. 
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Neutralizing Antibody Titer Determinations 
Antibody t itrations were done with all mice sera as described previ-
ously [ 4/. Only the ganglia of mice with detectab le ant ibody t ite rs were 
evaluated in the experiments. Mice without measurable ant ibody titers 
were considered as unsuccesfully infected animals. 
Planning of Experiments 
Since the experimental procedures required t he harvesting of large 
numbers of t rigeminal ganglia in a single day , t he experiments were 
done with 3 batches of infected mice. With the first group of mice we 
tested PFA, Ara-AMP, and ACV, with the second Ara-T and BVDU, 
and wi t h the last FIAC, FIAU, and FMAU. 
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RESULTS 
Effect of PFA, Ara-AMP, and ACV 
The effect of PFA, Ara-AMP, and ACV on the reactivation 
of HSV from latently infected tr igeminal ganglia explant cul -
tures is shown in Fig 1. It can be seen that PFA at a concen-
tration of 100 p.g/ml reduced the titer of reactivated virus by a 
factor of 4logw uni ts, and a concentration of 400 1-tg/ml prevents 
completely the reactivation of the latent virus . Ara-AMP at a 
concentration of 10 ~-tg/ml reduced the yield by 3 log10 units, 
and at 100 ~-tg/ml no infectious virus was detected in the 
homogenates of ganglia explant cultures. The comparable val-
ues for ACV were 1 and 5 p.gfm l, respectively. It appeared 
therefore that ACV was about 100 t imes more active than PFA 
and about 20 times more active than Ara-AMP. 
It should be mentioned that the individual virus t iters in 
homogenates of ganglia showed relative wide variation of up to 
2 log10 units. It was also observed that in some individual 
ganglia virus reactivation was completely prevented at drug 
concentrations 4-10 t imes lower t han the concentrat ions which 
prevented virus reactivation in all ganglia explant cultures. 
Effect of BVDU and Ara-T 
The effect of BVDU and Ara-T on the in vitro reactivation 
of HSV from latently infected tr igeminal ganglia was similar 
(Fig 2): concentration of 8 p.g/ml of the drugs in the explant 
culture medium prevented the detection of reactivated virus in 
all ganglia. However, at a concentrat ion of 0.5 p.gf ml BVDU 
reduced the average virus t iter about 3 X 10:1 times, whereas 
Ara-T only 2 X 10~ times. The difference was of about the same 
order at a concentration of 1 p.g/ml, but leveled off at higher 
drug concentrations. 
As in the previous experiment, the range of virus titers in 
individual ganglia homogenates was wide and virus-free ganglia 
homogenates were found in explant cul tures maintained at 
drug concentrations lower than 8 p.g/ ml. Overall, the effective-
ness of BVDU and Ara-T to prevent virus reactivation was 
similar to that of ACV. 
Effect of FIAC, FJA U, and FMA U 
The effect of FIAC, FIAU, and FMAU in preventing virus 
reactivation in explant cultures of latently infected trigeminal 
ganglia was similar (Table I): no infectious virus was detected 
in expla11t cul tures maintained in the presence of 8 p.gfml of 
the drugs. It appeared t hat FIAC was somewhat more effective 
than FIAU and FMAU: t he average virus t iters in ganglia 
homoge nates from explant cultures maintained in the presence 
of FIAC at concentrations of 0.125, 0.5, and 2 ~-tg/ml were 
reduced more t han t hose from explant cultures maintained in 
the presence of FIAU and FMAU at similar drug concentra-
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FtG 1. The effect of PFA (panel A), 
Ara-AMP (panel B) and ACV (panel C) 
on reactivation of HSV in explant cul-
tures of latently infected trigeminal gan-
glia. Individual ganglia were maintained 
for 4 days in the presence of increasing 
drug concentrations. At the end of the 
incubation period Lhe ganglia were 
washed, homogenized, and the virus titer 
determined in a plaque assay on Vero 
cells. Each point represents the virus 
titer in an individual ganglion. Points 
below the dotted line indicate ganglia 
specimens in which no virus was de-
tected. 
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FIG 2. The effect of Ara-T (e) and BVDU (0) on reactivation of 
HSV in explant cultures of latently infected trigeminal ga no-lia. For 
details see legend of Fig I. b 
tions. However, the difference was statistically not significant. 
Again , virus titers showed a wide range, and virus-free ganglia 
homogenates were detected at concentrations lower than 8 1-tg/ 
ml. The inhibition of virus reactivation by various concentra-
t ions of FIAC, FIAU, and FMAU was, in general, simi lar to 
that obtained by ACV, BVDU, and Ara-T. 
DISCUSSION 
The results of these experiments, as well as those of previous 
studies [1] showed that antiviral drugs can be classified accord-
ing to their quantitative requirements for the prevent ion of 
virus reactivation in explant cultures of latently infected gan-
glia. PAA and PFA can be placed in a first group requiring high 
concentrations for complete inhibit ion of virus reactivation. 
PAA and PFA exert their inhibitory action by blocking the 
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TABLE I. Effect of FIA C, FIA U, and FMA U on reactivation of HSV-1 in. explant cultures of latently infected mouse trigeminal ganglia 
FIAC FIAU FMAU 
Drug concentration 
Frequency of Mean tite r in ex plant 
culture medium ga nglia with of reactivated 
(!lg/ml) reactivated virus (log10 
virus units± SO) 
none 9/10 4.36 ± 0.62 
0.125 8/10 3.07 ± 0.60 
0.50 7/10 1.96 ± 0.86 
2.0 2/8 l.O 
8.0 0/8 
virus-induced DNA polymerase (5-8]. The second group con-
sists of Ara-A and Ara-AMP which are phosphorylated by 
cellular enzymes into trip hosphates [9-12). The triphosphates 
block viral DNA synthesis either by their incorporation into 
viral DNA [11 ,13] or by inhibition of the viral DNA polymerase 
(14-16). The quantitative requirements of Ara-A and Ara-AMP 
for the inhibi tion of HSV reactivation in vitro are about 5-10 
times lower t han those for PAA and PFA. All the other com-
pounds tested in our experiments, i.e. , ACV, Ara-T, BVDU, 
FIAC, FIAU, and FMAU, a re preferentially phosphorylated by 
the HSV -specific t hymidine kinase and further phosphorylated 
by cellular enzymes to t riphosphates. The trip hosphates of 
these drugs prevent virus synthesis by inhibiting the viral DNA 
polymerase [17-21). These compounds prevent virus reactiva-
tion in explant cu ltures of latently infected ganglia at doses 
50-100 times lower th an those needed with PAA and PFA. 
The data of our experiments indicate that the titer of reac-
t ivated virus in sensory ganglia is variable, and that no reacti-
vated virus was detected in some ganglia explant cultures 
maintained in the presence of drug concentrations lower than 
the doses required for the prevention of virus reactivation in 
all ganglia explant cultures. This would suggest that the inhi-
bition of virus reactivation is dependent not only on drug 
concentration , but also on other factors, such as the total 
number of latently infected neurons in the ganglia, and possibly 
on t he effectiveness of drug penetration in the explanted gan-
glia, or the rate of drug inactivation in the explant culture 
medium. 
We have described the activity of the tested drugs as an 
inhibition of the reactivation of HSV from latently infected 
ganglia. However, the absence of infectious virus does not 
necessarily mean that the process of reactivation was not 
initiated . .It is quite possible t hat reactivation was tr iggered by 
the removal of the ganglia from mice , but t he presence of drugs 
prevented the synthesis of infectious virus. Presently accumu-
lated data cannot yet distinguish between these two possibili-
ties, but the general inability of antiviral substances to e limi-
nate latent HSV infections would suggest that there is no 
interaction between drugs and the latent virus. 
We would like to thank Ei leen Brady and Lori Kaley for excellent 
techn ical ass ista nce, and Claudia Boake for secretarial help. 
REFERENCES 
l. Woh lenberg C, Openshaw H, Notkins AL: l n. vitro system for 
studyi ng the efficacy of antivira l agents in preventing the reac-
tivation of latent herpes simplex virus. Antimicrob Agents 
Chemother 15:625- 627, 1979 
2. Klein RJ, DeStefano E, F'riedman -Kien AE, Brady E: Effect of 
acyclovir on latent herpes simpl ex virus infections in trigeminal 
ganglia of mice. Ant.imicrob Agents Chemother 19:937- 939, 1981 
3. Park NH, Pavan-Langston D, DeClercq E: Effect of acyclovir, 
Frequency of Mean titer Frequency of Mean liter 
ganglia with of reactivated ganglia with of reactivated 
reactivated virus (Iog 1u reactivated virus (Iog10 
virus 
6/6 
6/6 
5/6 
2/6 
0/6 
units± SO) virus unit.s ±SO) 
4.56 ± 0.98 6/6 4.36 ± 0.33 
4.29 ± 0.39 6/6 4.16 ± 0.23 
3.37 ± 0.60 6/6 2.32 ± 1.26 
1.46 ± 0.12 3/6 1.64 ± 0.53 
0/6 
bromovinyldeoxyuridine, vidarabine, and L-lysine on latent gan-
glionic herpes simplex virus in vitro. Am J Med 73:151- 154, 1982 
4. Klein RJ , Friedman-Kien AE, Fondak AA, Buimovici-Klein E: 
Immune response and latent infection alter topical treatment of 
herpes simplex virus infection in hairless mice. Infect Immun 
16:842- 848, 1977 
5. Mao JCH, Robishaw EE, Overby LR: Inhibit ion of DNA polymer-
ase from herpes simplex virus- infected WJ -38 cel ls by phosphon-
oacetic acid . J Virol 15:1281- 1283, 1975 
6. Le inbach SS, Reno JM , Lee LF, Isbell AF' , Boezi JA: Mechanism 
of phospbonoacetate inhibition of herpesvirus- induced DNA po-
lymerase. Biochemistry 15:426-430, 1976 
7. Reno JM, Lee LF, Boezi JA: Inhibition of herpesvirus replication 
and herpesvirus-induced deoxy ribonucleic acid polymerase by 
phosphonoformate. Antim icrob Agents Chemother 13:188-192, 
1978 
8. Helgstrand E, Euiksson B, Johansson NG, Lannero B, Larsson A, 
Misiorny A, Noren ,JO, Sjoberg B, Stenberg K, St.ening G, Stridh 
S, Oberg B, Alenius S, Philipson L: Trisodium phosphonofor-
mate , a new antiviral compound. Sc ience 201:819- 821, 1978 
9. Brink JJ, LePage GA: Metabolism and distribut ion of 9-{j-D-
arabinofuranosyladenine in mouse tissue. Cancer Res 24:1042-
1049, 1964 
10. llan J , Tokuyasu K, Ilan J: Phosphorylation of D-arab inosyladen-
ine by Plasmodium berghei and its partial protection of mice 
against malaria. Nature 228:1300- 1301, 1970 
ll. Plunkett W, La pi L, Ortiz PJ, Cohen SS: Penetration of mouse 
fibroblasts by the 5' -phosphate of 9-/3-D-arabinofuranosyladen-
ine and incorporation of the nucleotide into DNA. Proc Nat! 
Acad Sci USA 71:73- 77, 1974 
12. LePage GA: Arabinosyladenine and arabinosylhypoxanthine me-
tabolism in murine tumor cells. Can J Biochem 48:75-78, 1970 
13. Wagner MA, Burgoyne LA, Atkinson MR: Deoxyribonucleic acid 
synthesis in mammalian nuclei: incorporation of deoxyribonu-
cleotides and chain-terminating nucleotide analogues. Biochem 
J 121:803- 809, 1971 
14. Furth JJ, Cohen SS: Inhibi t ion of mammalian DNA polymerase 
by the 5' -triphosphate of 9-/3-0-arabinofuranosyladenine. Can-
cer Res 27:1528-1533, 1967 
15. York JL, LePage GA: A proposed mechanism for the action of 9-
fi-D-arabinofuranosyladenine as an inhibitor of the growth of 
some asc ites cells. Can J Biochem 44:19- 26, 1966 
16. Falke D, Ronge K, Arendes J, Muller WEG: Differential and 
selective inhibition of cellular and herpes simplex virus DNA 
synthesis by arabinofuranosyladenine. Biochi m Biophys Acta 
563:36-45, 1979 
17. Elion GB, Furman PA, Fyfe JA, DeMiranda P, Beauchamp J , 
Schaeffer HJ: Selectivity of action of an anti herpetic agent , 9-
(2-hydroxyelhoxymelhyl)guanine. Proc Nat! Acad Sci USA 
74:5716- 5720, 1977 
18. Furman PA, StClair MH, Fyfe ,JA, Rideout JL, Kel ler PM, Elion 
GR: Inhibition of herpes simplex virus- induced DNA polymerase 
activity and viral DNA replication by 9-(2-hydroxyet.hoxyme-
thyl)guan ine and its triphosphate. J Virol 32:72- 79, 1979 
19. Aswell JF, Allen GP, Jamieson AT, Campbell DE, Gentry GA: 
Antiviral activ ity of arabinosylthymine in herpesviral replica· 
t1on: mechanism of action in vivo and in vitro. Antimicrob 
Agents Chemother 12:243-254 , 1977 
20. Allaudeen HS, Kozarich JW, Be rtino ,JR, DeClercq E: On the 
mechanism of selective inhibition of herpesvirus replication by 
(E)-5-(2-bromovinyl) -2' -deoxyuridine. Proc Nat! Acad Sci USA 
78:2698- 2702, 1981 
21. Lopez C, Watanabe KA, F'ox JJ: 2' -Fluoro-5- iodoaracytosine, a 
potent a selective anti-herpesvirus agent. Antimicrob Agents 
Chemother 17:803- 806, 1980 
